Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184212 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2HPGDALDH1A1LMNAHTT | |
| SCHEMBL4204380 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2HPGDALDH1A1LMNAHTT | |
| SCHEMBL4197445 | 0.86 | KMT2A (0.48) | SMN1; SMN2ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL4196629 | 0.86 | KMT2A (0.48) | SMN1; SMN2ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL4195095 | 0.86 | KMT2A (0.48) | SMN1; SMN2ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL4192672 | 0.86 | KMT2A (0.52) | SMN1; SMN2ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL4192548 | 0.83 | KMT2A (0.47) | SMN1; SMN2HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL4195568 | 0.82 | METAP2 (0.40) | SMN1; SMN2HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL4196854 | 0.80 | KMT2A (0.42) | KMT2AMEN1NPSR1L3MBTL1 | |
| SCHEMBL4196799 | 0.80 | CCR3 (0.50) | SMN1; SMN2ALDH1A1HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | SMN1; SMN2 3369/4885HPGD 2593/4885ALDH1A1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.